CI Stock Price Today (October 2026) — The Cigna Group Analysis & Key Metrics 2026-10-07
The Cigna Group (CI) is trading at $278.51, up 1.51% today (as of October 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $341.04 (22.5% upside).
- Volatility is low (16.66% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.70% YoY) alongside competitive pressures in the Healthcare Plans space.
CI Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
The Cigna Group - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $98.21B
P/E Ratio
Forward P/E: 8.24
Revenue Growth
Year over Year
Analyst Target
+22.5% upside potential
Key Investor Questions About CI
What investors need to know before buying
Based on current market data, CI presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 57.38)
- Fundamentals say: Looking solid (debt and growth supportive)
CI's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CI investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $31.88B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CI stock traded between $239.51 and $315.47 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 16.66% annualized volatility and β=0.17, the stock exhibits low sensitivity to market moves—making CI suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Did UnitedHealth Name The Fix Before Its Stock Ran?
UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.
Can Cigna's AI Push Help Rein In Rising Healthcare Costs?
CI is expanding AI across care coordination and specialty pharmacy as it seeks to manage elevated healthcare costs and improve access.
Is Cigna Group (CI) Still Undervalued Or Are The Risks Keeping It Fairly Priced?
Cigna Group (CI) continues to draw attention after its recent close at US$288.90, with investors weighing modest return figures across the past week, month, and past 3 months against the insurer's broader long term track record. Recent trading has been more mixed for Cigna Group, with the share price slipping 0.4% on the day but still posting a 4.7% 7 day gain and a 3.5% year to date share price return. The 1 year total shareholder return of 0.4% and 5 year total shareholder return of 56.7%...
CVS Stock Returned $24B In Cash: Why Did It Still Lag The Market?
The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here’s the accounting of what that trade-off actually delivered.
Should You Buy UNH Stock Because Its Cash Runs Ahead Of Its Profit?
UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.
Should You Buy Elevance Health Stock For The Margin It Lost?
Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.
Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?
CVS is benefiting from pharmacy growth, AI investments and a discounted valuation, but reimbursement pressure and regulatory scrutiny remain key risks.
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
Why Is UNH Stock Trading At A Premium With The Slowest Growth?
UnitedHealth (UNH) runs the best operating margin of the three managed care companies in its peer group, and the slowest revenue growth of the three. It also carries a significant valuation premium over its peer, Cigna, trading at more than double its earnings multiple.
Cigna Group Executive Neville Everett Sells 617 Shares for $175,000
Everett disposed of 11% of his direct equity holdings under a pre-arranged Rule 10b5-1 trading plan, leaving a stake valued at $1.45 million.
Explore More Analysis for CI
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (before the open)
Frequently Asked Questions
Common investor questions about The Cigna Group
The Cigna Group (CI) is currently trading at $278.51. The RSI (14-day) is at 57.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $341.04 implies 22.5% upside from current levels. Volatility is low at 16.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for The Cigna Group (CI): The trailing P/E ratio is 12.12, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 8.24, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.83, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.79. Price-to-Sales is 0.27. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering CI, the consensus price target is $341.04. This represents a 22.5% upside from the current price of $278.51. The range spans from a low target of $288.00 to a high target of $400.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, The Cigna Group (CI) pays a dividend with a current yield of approximately 2.24%. The annualized dividend rate is $6.14 per share. The payout ratio is 25.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Sep 8, 2026.
Key risks for The Cigna Group (CI) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is The Cigna Group's (CI) current debt and financial health profile: Total debt stands at $31.88B. The debt-to-equity ratio is 0.74x, which is moderate and generally manageable for most companies. The current ratio is 0.85, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.69. The company holds $7.26B in cash and equivalents. Free cash flow is positive at $7.98B, providing a cushion for debt servicing and shareholder returns.